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Abstract 
Keratan sulphate (KS) is a bioactive glycosaminoglycan (GAG) of some 
complexity composed of the repeat disaccharide D-galactose 1→4 
glycosidically linked to N-acetyl glucosamine. During the biosynthesis of KS a 
family of glycosyl transferase and sulphotransferase enzymes act sequentially 
and in a co-ordinated fashion to add D-galactose (D-Gal) then N-acetyl 
glucosamine (GlcNAc) to an GlcNAc acceptor residue at the reducing 
terminus of a nascent KS chain to effect chain elongation.  D-Gal and GlcNAc 
can both undergo sulphation at C6 but this occurs more frequently on 
GlcNAc than D-Gal.  Sulphation along the developing KS chain is not 
uniform and contains regions of variable length where no sulphation occurs, 
regions which are monosulphated mainly on GlcNAc and further regions of 
high sulphation where both of the repeat disaccharides are sulphated.  Each 
of these respective regions in the KS chain can be of variable length leading to 
KS complexity in terms of chain length and charge localization along the KS 
chain. Like other GAGs it is these variably sulphated regions in KS which 
define its interactive properties with ligands such as growth factors, 
morphogens and cytokines and which determine the functional properties of 
tissues containing KS.  Further adding to KS complexity is the identification 
of three different linkage structures in KS to Asparagine (N-linked) or to 
Threonine or Serine residues (O-linked) in proteoglycan core proteins which 
has allowed the categorization of KS into 3 types, namely KS-I (corneal KS, N-
linked), KS-II (skeletal KS, O-linked) or KS-III (brain KS, O-linked). KS-I to III 
are also subject to variable addition of L-fucose and sialic acid groups. 
Furthermore, the GlcNAc residues of some members of the mucin-like 
glycoprotein family can also act as acceptor molecules for the addition of D-
Gal and GlcNAc residues which can also be sulphated leading to small low 
sulphation glycoforms of KS.  These differ from the more heavily sulphated 
KS chains found on proteoglycans.  Like other GAGs, KS has evolved 
molecular recognition and information transfer properties over hundreds of 
millions of years of vertebrate and invertebrate evolution which equips them 
with cell mediatory properties in normal cellular processes and in aberrant 
pathological situations such as in tumourogenesis. Two KS-proteoglycans in 
particular, podocalyxcin and lumican are cell membrane, intracellular or 
stromal tissue associated components with roles in the promotion or 
regulation of tumour development, mucin-like KS-glycoproteins may also 
contribute to tumourogenesis. A greater understanding of the biology of KS 
may allow better methodology to be developed to more effectively combat 
tumourogenic processes.   
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Please note that the KS antibodies refer to in this chapter are directed to 
epitopes in the glycosaminoglycan keratan sulphate and should not be 
confused with anti-aminoacyl-tRNA synthetase (ARS) antibodies which have 
also been referred to as KS antibodies 1 or the anti-cyclin D1/D2 antibody 
which is also referred to as 5-D-4 2. 
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1. Introduction  
 Glycosaminoglycans (GAGs) have evolved over hundreds of millions 
of years of vertebrate and invertebrate evolution through positive 
evolutionary selection pressures which have resulted in GAGs being chosen 
which have an ability to participate in a diverse range of essential 
physiological processes 3,4. GAGs are sophisticated biodiverse components of 
the glycocalyx surrounding all cells which convey important molecular 
recognition and structural information important in cellular regulation and 
tissue homeostasis 5-10.  While GAGs are composed of regular repeat 
disaccharides it is the non-uniform sulphation patterns along the GAG 
backbone which have important extracellular matrix and cell regulatory 
properties and these are the functional determinants on GAGs which equip 
them with interactive properties with extracellular matrix (ECM) components, 
growth factors, morphogens and cytokines which regulate tissue 
development/remodelling and the maintenance of tissue homeostasis in 
health and disease 5,11-14. Significant alterations in GAG distributions and 
composition have been noted in a number of tumours, these are of diagnostic 
value and tumour secretions containing these GAGs have proven useful as 
biomarkers of the pathological status of tissues and the degree of tumour 
development or regression following therapeutic intervention 15,16.   
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2. Keratan Sulphate Structure 
 Keratan sulphate (KS) is a GAG which has a widespread distribution in 
connective tissues 17,18. KS is composed of the 1-4 glycosidically linked repeat 
disaccharide Gal-GlcNAc which are sulphated at C6 either individually or 
collectively leading to regions of mono or disulphation in the KS chain, 
regions of non-sulphation have also been identified referred to as (poly) N-
acetyl lactosamine regions in the KS chain although a number of proteins also 
contain lactosamine (Figure 1). The linkage region at the reducing terminus of 
the KS chain to proteoglycan (PG) core protein acts an acceptor molecule for 
saccharide attachment. During KS biosynthesis chain elongation and 
sulphation are co-ordinated events and elongation of the KS chain occurs by 
step-wise addition of GlcNAc or Gal co-ordinated with sulphation of these 
moieties 17,18.  Several glycosyl transferases and sulphotransferases are 
involved in KS biosynthesis, these are shown in Figure 2 reproduced from 
KEGG KS biosynthesis reference data  (Map 00533) 
[http://www.kegg.jp/kegg-bin/show_pathway?map00533]. GlcNAc 6-O-
sulphotransferase acts only on terminal non-reducing terminal GlcNAc 
residues on the nascent KS chain. Failure to add sulphate to a terminal 
GlcNAc residue may result in a disaccharide unit devoid of sulphate or 
having one sulphate group located on the GlcNAc residue only, D-Gal 
sulphotransferase only acts on a KS disaccharide if the GlcNAc is first 
sulphated giving rise to a disulphated disaccharide thus heterogeneous 
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distributions of mono- or disulphation or non-sulphation can also occur along 
a given KS chain. GlcNAc normally undergoes sulphation more frequently 
than Gal in the KS disaccharide.  Like all GAGs the sulphation status of KS 
defines its functional properties. 
 
2.1 Keratan sulphate biodiversity 
 KS has been categorised into three types on the basis of differences in 
the structures of the linkage region they utilise to attach to PG core proteins 
and in their internal structural organisation (Figure 1).   KS-I was the first 
form of KS identified, cornea is the richest tissue source of this GAG leading 
to its historical naming as corneal KS 19, however this form of KS also 
decorates a number of PGs with a widespread tissue distribution in a range of 
tissues other than the cornea thus its naming is a historical misnomer.  KS-II 
or skeletal KS exclusively decorates the major cartilage PG aggrecan.  A 
further form of KS has been identified in brain (KS-III) which is rare in non-
neural tissues but occurs in ~30% of all brain glycoproteins and PGs (Figure 
1). 
 Corneal KS (KS-I) is attached to Asn in PG core proteins via a complex-
type N-linked branched oligosaccharide, whereas in cartilage, KS-II is O-
linked via GlcNAc to Ser or Thr residues via a mucin core-2 structure 17.  Brain 
KS-III uses a third type of linkage to protein via mannose O-linked to Ser or 
Threonine 20. These linkage oligosaccharides are shown in Figure 1.  KS is a 
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heterogeneous GAG and exhibits both variation in chain length and in 
sulphation along the KS chain. Five regions can be identified in KS-I, (i) the 
non reducing terminal end-capped region, (ii) di-sulphated region, (iii) 
monosulphated region, (iv) non sulphated lactosamine region, (v) the linkage 
region to PG core protein.  Equivalent regions in KS-II and KS-III also occur 
but the lengths of individual regions and sulphation patterns may differ 
leading to a considerable level of size and charge heterogeneity in KS.  
Furthermore, the size distribution and degree of sulphation of KS chains 
increases with tissue development and maturation and the age of the 
connective tissues and its pathological status.  High charge density KS has 
been observed associated with a number of tumours thus its analysis can be 
of diagnostic value. 
 In porcine corneal KS, the C-6 branch of the linkage oligosaccharide is 
extended but the C-3 branch is terminated by a single lactosamine capped by 
sialic acid 21. Sulphation in porcine corneal KS is distributed non-randomly, 
two non-sulphated lactosamine disaccharides are present nearest the 
reducing terminus but 10–12 sulphated GlcNAc disaccharides are found on 
the more distal part of the chain. The non-reducing terminal region is of 
variable length and contains disulphated GlcNAc and Gal disaccharides 
sulphated at C6  22-39. Corneal KS displays a single branch in the linker 
oligosaccharide, extension of the other branch in the biantennary 
oligosaccharide is also occasionally possible [reviewed in 18. The non-reducing 
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ends of KS-I chains are terminated with neuraminic acid, βGalNAc, or αGal 
end-capping structures 39,40.  Despite its name, KS-I is found in tissues other 
than the cornea such as in cartilage N-linked KS chains occur on 
fibromodulin, lumican, PRELP (prolargin), keratocan and osteoadherin 22,25,38. 
Aggrecan contains 2–3 N-linked KS chains in addition to 20 or more O-linked 
KS-II chains in the KS rich region adjacent to CS substituted regions on the 
aggrecan core protein 24. A few KS chains are also interspersed in the CS1 and 
CS-2 regions in aggrecan these differ from the KS chains of the KS rich region 
in that they can be heavily modified by fucosylation and sialylation making 
them immunologically distinguishable. The amino terminal G1 and G2 
globular domains of aggrecan and the interglobular domain (IGD) between 
these contain a few small KS chains however these are of low sulphation and 
can be N- or O-linked.  Some of these KS chains in G1 obscure T cell epitopes 
which otherwise make the G1 domain a potent arthritogen in inflammatory 
arthritis.  KS chains within the IGD potentiate the action of ADAMTS-4 and  
ADAMTS-5 which cleave in the IGD and elsewhere in the aggrecan core 
protein.  These enzymes are important for aggrecan turnover however 
excessive ADAMTS activity results in cartilage degeneration and pathological 
tissue changes in OA and RA.   PZP3 zona pellucida glycoprotein carries KS-I 
chains however these differ from the KS-I chains found in cornea 36. Similarly, 
KS-I in fibromodulin is relatively short (8–9 disaccharides), more highly 
sulphated 34 and lacks the characteristic domain structure of corneal KS and 
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its non-reducing terminal end-capping saccharides resemble those found in 
cartilage KS-II rather than corneal KS-I 34, thus such capping structures are 
tissue-specific rather than KS type specific. KS-II in the KS rich region of 
aggrecan, contains 5–11 highly sulphated disaccharides, interrupted only 
occasionally by mono-sulphated KS and its non-reducing terminal region is 
capped by neuraminic acid attached at C3 or C6 to  terminal GlcNAc.  
Furthermore fucose is attached to C3 of sulphated GlcNAc throughout the KS 
chain but not within four residues of its non-reducing terminus 26. KS-II from 
non-weight bearing tracheal cartilage is not fucosylated, and carries only 
(2→3) linked neuraminic acids at the non-reducing terminus 27,35.  
 
2.2 Keratan sulphate antibodies 
 Monoclonal antibodies to KS (Table I) react with extracts from most 
mammalian tissues, at least sixteen ECM PGs substituted with KS and several 
intracellular and cell associated KS-PGs have been identified [reviewed in 
17,18]. All GAGs other than KS contain at least one negative charge per 
disaccharide, the lack of uronic acid in KS and variable sulphation of its 
lactosamine residues results in charge heterogeneity in KS 17,18.  Furthermore, 
a number of poly-N-acetyl lactosamine modified proteins exist which would 
be classified as KS-PGs if some of their residues were sulphated 32. The 
development of MAb R10G and 1B4 allows KS-PG species of low sulphation 
and mucin-like proteins containing lactosamine regions containing GlcNAc 
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and Gal residues that are sulphated to be identified as KS-PGs (Figure 3).   
Formerly, antibodies such as 5D4 and MZ-15 which detect high charge 
density KS glycoforms were routinely used in this research area however 
these do not detect such low sulphation forms of KS thus a new aspect of the 
biology of KS-PGs of low sulphation is now emerging 41-43.     
 
2.3  Keratan Sulphate complexity in healthy and diseased tissues 
KS and its specific roles in tumours, spinal cord and brain 
 Analysis of GAGs associated with normal and tumour tissues and 
tumour cells 15,44-54 and their secretions 48,55 has identified the glycan signatures 
of pathologic tumourogenic tissues and shown these are of diagnostic and 
prognostic value 15,56.  Changes in the PG compositions associated with 
tumour masses have also been identified 57,58.   KS is a prominent component 
of many tumours including carcinomas of the genital tract 56, prostatic 
secretory cells 44, brain and ovarian tumours 53, papillary carcinomas of the 
human thyroid gland 59 and granular cell tumours 45.  The human embryonal 
carcinoma marker antigen TRA-1-60 identifies a sialylated KS-PG 60. 
Chondrosarcoma cells synthesise a characteristic KS-PG in long-term culture 
57.  Improved methodologies have been developed for the structural 
characterisation of KS produced by ovarian and brain tumours 53.  KS-
substituted isoforms of thyroglobulin and transferrin are uniquely elaborated 
in papillary thyroid carcinomas 61.  Highly sulphated KS is synthesized in 
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malignant astrocytic tumours 47,62, and glioblastoma 46. Lumican is a 
prominent KS-PG associated with a number of tumours (Table III) and has 
roles in the regulation of tumour cell growth, migration and attachment to 
ECM components 63-66.  Another KS-PG, podocalyxcin has also been found 
associated with malignant astrocytic tumours 62.  Monoclonal antibody 4C4 
specifically recognizes KS-PG on human embryonal carcinoma cells 67.  KS has 
been identified as a prominent component of pathological brain tissues.  KS is 
produced by microglial cells in the development of amyotrophic lateral 
sclerosis (ALS)68-71.  A reduction in KS levels in brain tissues accelerates the 
development of ALS 72 and Alzheimer’s disease (AD) 73,74. 
 
 In the intact normal spinal cord, microglial cells and macrophages 
express the 5D4 KS epitope however astrocytes do not 75.  A focal 
upregulation of 5D4 reactivity occurs associated with glial scar formation 
following spinal cord injury apparently due to glial cell activation and an 
influx of macrophages to the lesion site (Figure 4).  Proteoglycans are up-
regulated in the spinal cord lesion site and this stabilises this structure 
however the KS and CS side chains of these PGs strongly inhibit nerve 
outgrowth and axonal regeneration 76-78. Therapeutic administration of 
keratanase, chondroitinase B and chondroitinase ABC significantly improves 
spinal cord regeneration in experimental rat models and suggesting these as  
appropriate therapeutic interventions to improve recovery of human spinal 
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cord injury 76,79,80. Fragmentation of aggrecan occurs in the normal intact spinal 
cord through the action of aggrecanase and metalloprotease  enzymatic 
activity and the abundance of aggrecan fragments increases with spinal cord 
injury81-86.  Up-regulation of ADAMTS-4, 5 in the spinal cord lesion site is 
associated with areas of improved repair post injury and these have been 
suggested to be of therapeutic value however these findings need to be 
carefully evaluated 84,87.  
 
 KS also has roles in the pathogenesis of ALS and in the activation and 
proliferation of microglial cells 69.  KS binds to Shh and regulates the 
differential switch from motor neuron to oligodendrocyte during spinal cord 
development 88.  Phosphacan containing high charge density 5D4 positive KS 
chains regulates the development of the mouse visual cortex 89. KS inhibits 
neural regrowth 90 and directs the development of the trigeminal nerve 
during corneal development 91. KS has interactive properties with a large 
number of nerve regulatory proteins through which it can regulate neural 
development through interaction with members of the Robo, Slit, Ephrin, 
Ephrin receptor and Semaphorin families and two further nerve growth 
factor receptors 92 
 
2.3.1 Mucin type glycoproteins:  
The role of KS substitution in tumour development 
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 Membrane bound and secreted mucin type glycoproteins contain 
GalNAc, GlcNAc, Gal, Fuc, N-acetyl neuraminic acid attached to their core 
proteins through O-linkage to Ser and Thr residues on their tandem repeat 
domains leading to a bottle brush type structure reminiscent of PGs such as 
aggrecan (Table II).  A family of sulphotransferases can sulphate the GlcNAc 
and Gal residues in mucins thus some mucins carry KS chains 93, MUC1, 
MUC4, and MUC16 synthesised by normal cultured bronchial epithelial cells 
bear 5D4 positive KS 94.  MUC16 is the largest transmembrane mucin with a 
molecular weight ranging from 2.5 to 5 MDa.  MUC16 lubricates and protects 
the mucosal epithelium of the upper respiratory tract, ocular surface, 
mesothelial pleural, peritoneal and lining tissues of the male and female 
reproductive organs.  MUC16 contains extracellular and transmembrane 
domains as well as a cytoplasmic domain which interacts with the ERM 
cytoskeletal actin-binding proteins ezrin, radixin and moesin.  MUC16 is also 
associated with tumour cells, its extracellular domain is cleaved from ovarian 
cancer cell surfaces into the blood stream where it is useful as a tumour 
biomarker through identification of a peptide epitope (CA125) which also 
promotes cancer cell proliferation 41,42,95.  Cultured human tracheobronchial 
epithelial cells synthesise 5D4 KS positive MUC1, MUC4, and MUC16 
tethered to cilia and microcilia however no PGs have been detected in the 
epithelial glycocalyx (Figure 5). KS on the mucin associated cilia and ciliary 
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plumes provide a protective layer extending as far as 100 m from the 
epithelial cell surface 94. 
 
 The sulphated glycans on epithelial mucins effect cell adhesion and 
regulate the biosynthesis, half-life and biological roles of glycoproteins 
controlling lymphocyte homing and inflammation in the epithelial mucosa.  
Two sulphotransferase families transfer sulphate from 3-phosphoadenosine 5-
phosphosulphate (PAPS) to C3 of Gal (Gal3ST) or C6 of GlcNAc (GlcNAc6ST) 
in mucins.  The ubiquitous mucin core 1Gal3ST, acts on O-linked Galβ1–
3GalNAc α-R in most tissues, with high activity levels in rat colonic mucosa 
and is also upregulated in inflamed cartilage, intestine and lung tissues in 
tumour development.  KS has been immunolocalised to the cell associated 
mucins MUC1, MUC4 and MUC16 94. O-glycan mucin core structures 1–4 and 
6 act as potential substrates for sulphotransferases 96-100, sulphation on Gal and 
GlcNAc residues of N-acetyl lactosamine occurs at C3 of Gal and C6 of 
GlcNAc 93.  Human mammary epithelial cells synthesise PGs containing O-
linked sulphated GlcNAc attached to core 2 structures 101 (Table 2). MUC-1 in 
human endometrial tissue carries 5D4 positive KS and a sialo-KS epitope 
recognized by Mab D9B1 102.  These epitopes convey adhesive and anti-
adhesive properties which regulate embryo implantation 102. These KS 
epitopes are independently regulated in the endometrial endothelium due to 
hormonal control with the 5D4 epitope abundant on the luminal epithelial 
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surface until implantation, thereafter it gradually disappears, D9B1 binding 
sites are retained in the luminal endometrial epithelium following 
implantation 103. 
 
 An endothelial mucin-like adhesion molecule (Glycam-1) binds L-
Selectin through C6 sulphated GlcNAc and Gal on O-linked Sialyl LewisX like 
structures 104,105.  Sulphation of Sialyl LewisX structures significantly improves 
their L-Selectin binding properties. The sulphation motifs on mucins act as 
binding modules for bacteria but also protect the mucins from 
depolymerisation by bacterial glycosidases.  Changes in mucin sulphation 
alter growth factor interactions, leucocyte homing and adhesion under 
inflammatory conditions 106.  In monocytes TNF induces expression of 6-
sulfo N-acetyl lactosamine (LacNAc)/Lewis X epitopes on N-and O-linked cell 
surface glycans altering their migratory and adhesive properties 106.  Cell 
surface and secreted mucins in ovarian cystadenoma 107 or human bronchial 
mucins 33,108 also carry such sulphated Lewis X L-selectin ligands which 
promote leucocyte attachment to the endothelium 109-111. The sulphate content 
of mucins is decreased in colon cancer and in ulcerative colitis 112-115 due to 
degradative effects on mucins by bacterial sulphatase activity 116.  A 
significant reduction in mucin sulphation has also been observed in colorectal 
adenoma cells as they progress to a cancerous state. This decrease is due to 
decreased core 1 Gal3ST and GlcNAc6ST expression 117. Lower Gal3ST activity 
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is also a feature of colon cancer 118-120 and breast cancer cells compared to 
normal mammary cells 96. The mucin core structures biosynthesized and their 
associated modifications in cancer 120 influence the amount of mucin 
sulphation. Alterations in the expression patterns of sulphated mucins and 
sulphotransferases in inflammatory diseases and cancer alters the distribution 
and density of mucin sulphation motifs and adversely influencing disease 
progression 93. 
 
3. Brain contains a number of multifunctional KS-PGs 
A number of diverse KS substituted PGs have been identified in the brain 
(Figure 6).  Aggrecan is a component of perineuronal nets which surround 
and protect neurons and promote neuritogenesis and synaptic plasticity  121.  
Podocalyxcin is a transmembrane KS-PG with cell signalling capability 
widely distributed in neurons.  In embryonic tissue podocalyxcin isolated 
from pluripotent neuroprogenitor cells contains low sulphation KS chains and 
has been used as an antigen for the production of antibodies which identify 
these low sulphation KS glycoforms.  However in pathological neural tissues 
tumour cells express podocalyxcin decorated with high charge density KS 
glycoforms identified by antibodies 5D4, and MZ-15 122,123 and these may also 
be of diagnostic value (Figure 6). 
 
 Podocalyxcin is an anti-adhesive transmembrane neural KS-
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polysialylated- proteoglycan/glycoprotein with essential roles to play in 
neural development 124,125 and is also a marker of human embryonic and 
induced pluripotent stem cells 126.   Podocalyxcin is upregulated in 
glioblastoma formation and in astrocytomas 46,47,62,127-130, and has been 
developed as a prognostic factor for various cancers 131,132.  The sulphation 
status of the KS chains on podocalyxcin on normal embryonic cells and 
tumour cells differ with the former expressing a low sulphation KS detected 
by MAb R-10G 133-135 while tumour cells produce a high sulphation KS chain 62 
detected by antibodies such as 5-D-4, MZ-15 or 4C4 67,122,123.   
 
 Two cytosolic adaptor proteins, Na+/H+-Exchanger Regulatory Factor 
2 (NHERF2) and Ezrin, interact with the cytoplasmic tail of podocalyxcin in 
kidney and similar interactions with cytoskeletal components also occur in 
neural tissues exerting regulatory effects on cell signaling and downline 
effects on neural behavior during the development and repair of the 
CNS/PNS136,137. Neural migration and axonal guidance are governed by cues 
from many ECM molecules (Netrins, Semaphorins) which exert either 
attractive or repulsive cues.  Podocalyxcin is not essential for neural migration 
to occur but can modulate this process 121. Cell-cell contact and adhesion to 
the ECM contribute to neural assembly processes.  Adhesion molecules such 
as NCAM and L1 have important roles to play in axonal growth, neural 
migration and synapse formation.  Co-ordination of ECM signals is essential 
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in such developmental processes.  Podocalyxcin has essential roles to play in 
neuritogenesis and synaptogenesis 138-140. Podocalyxcin co-localises with 
synapsin and synaptophysin in synapse vesicle formations 124. Synaptophysin 
is a major synaptic vesicle protein which co-ordinates the endocytosis of 
synaptic vesicles during neural stimulation 141, synapsin tethers synaptic 
vesicles to cytoskeletal components preventing  premature vesicle release into 
the synaptic gap co-ordinating neurotransmitter release from the synaptic 
vesicles 142-145.  
 
4. SLRPs and their roles in cell migration, proliferation and regulation of 
growth factors and inflammatory cytokines in a diverse range of tissues in 
health and disease. 
 The SLRPs have multiple functional roles in soft connective tissue 
ECMs where they regulate collagen fibrillogenesis and regulate growth factor 
and inflammatory cytokine activities (Figure 7).  Not only do the SLRPS 
maintain the integrity of tissues but their levels are elevated in OA and RA 146 
and in animal models of OA 147.  Lumican binds to C1q and regulates 
complement activation contributing to innate immune protection 148 and may 
also contribute to the OA/RA pathogenic processes.  Specific SLRP members 
such as lumican regulate cell migration and proliferation and have roles to 
play in tumour growth, local invasion, extravasation and invasion of remote 
anatomic sites  65. 
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 Lumican plays essential roles in the regulation of collagen 
fibrillogenesis in different ECMs however there is considerable redundancy in 
the SLRPs.  Lumican is also expressed in the developing bone matrix. Real-
time PCR OF MC3T3-E1 cell cultures showed that the expression of lumican 
increased as the osteoblast culture differentiated, suggesting a role for 
lumican in the regulation of collagen fibrillogenesis in bone matrices 149. 
During early embryonic murine development (E11 to E13), lumican is mainly 
expressed in the cartilaginous rudiments however by E14 to E16 lumican 
expression is more prominent in the developing bone. Lumican is secreted by 
differentiating and mature osteoblasts and can be used as a marker to 
distinguish proliferating pre-osteoblasts from the differentiating osteoblasts 
149. Lumican, keratocan and osteoadherin are all class II SLRPs 150 which 
interact with TGF-β, BMP4, WISP-1 (Wnt1-inducible secreted protein-1), von 
Willebrand factor, PDGF, TNF-α, and IGF-I  forming growth factor 
concentration gradients controlling their  bioavailability to cells and 
pericellular interactions they participate in with cell-surface receptors, 
modulating cell-ECM interactions which modulate tissue development and 
homeostasis 150.   Osteoadherin (osteomodulin) is a 49,116-Da protein 
containing 11 leucine-rich repeats (LRRs), 3-4 tyrosine sulphate residues at the 
N-terminus , and six potential glycosylation sites for N-linked KS chains  
within the LRR region. Osteoadherin shows 42% sequence homology to 
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keratocan and 37–38% identity to fibromodulin, lumican, and PRELP 38. 
Osteoadherin promotes αvβ3- integrin mediated cell binding.  Osteoadherin 
has been isolated as a minor, leucine- and aspartic acid-rich KS-PG found in 
the mineralized matrix of bone 151.   Osteoadherin is a relatively acidic protein 
which binds to hydroxyapatite and to osteoblasts through αvβ3- integrin and 
has been immunolocalised to pre-dentin during tooth formation 152. 
 
5. Lumican specific roles in the regulation of tumour development 
 Lumican is a class II SLRP which bears significant levels of homology 
with other class II SLRPs such as keratocan, fibromodulin, lumican, and 
PRELP.  Lumican is the only SLRP which occurs with such a high frequency 
in tumourogenic tissues leading to the proposal of lumican as a tumour cell 
marker. 
 SLRPs organize the cartilaginous and many other soft connective tissue 
ECMs where they have functional roles to play in tissue development, 
remodelling and in pathogical changes in these tissues 146. OA is a progressive 
degenerative condition affecting the articular cartilage, meniscus, synovium, 
subchondral bone and infrapatellar fat pad in the knee-joint 153,154.  With the 
development of OA, PGs in these tissues undergo proteolytic degradation 
and some of the fragments so generated have been suggested as potential 
biomarkers of this disease process.  Characteristic fragmented forms of the 
 21 
CS/DS substituted PGs aggrecan, decorin and biglycan also occur in OA.  
Fibromodulin and Lumican are structurally homologous sharing 47% identity 
in  their primary structures and both can have 4 small N-linked KS chains 
155,156. Like all class II SLRPs fibromodulin  and lumican contain 11 LRRs 
which facilitate their interactions with other ECM components including type 
I and type II collagen which regulates fibril spacing and the fibrillogenesis 
process.  Lumican regulates the regularly orthogonally spaced fine collagen 
fibrillar arrangements in the cornea essential for optical clarity 157-163. 
Fibromodulin is more prominent in the limbus and sclera where it stabilises 
large collagen fibre assembly which mechanically support the eye-ball 159,164,165. 
Fibromodulin has N-linked KS attachment sites on Asn residues at positions 
127, 166, 201,291, and 341 in the core protein although only four of these sites 
are occupied by KS at any one time. Lumican also contains four N-linked KS 
chains located within the central LRR region at Asn 88, 127, 160, and 252. In 
addition, both of these SLRPs contain N-terminal sulfated tyrosine clusters, 
with  fibromodulin containing up to nine of these residues and lumican two 
148,166, this localization of charge facilitates interactions with growth factors in a 
similar manner to HS interactions with growth factors. 
 Despite this similarity in structural form ADAMTS-4, ADAMTS-5 167, 
MMP-2,-3,-13 and -14 variably degrade fibromodulin and lumican during the 
etiopathogenesis of OA 168, releasing intact or fragmented forms of 
 22 
fibromodulin or lumican from articular cartilage, meniscus and other joint 
tissues.  These SLRP fragments act as DAMPs activating TLR-2 and -4 
initiating innate inflammation, and pain pathways 169,170.  Lumican also 
augments LPS signaling through cell surface CD14, a bacterial 
lipopolysaccharide co-receptor which interacts with TLRs leading to NF B 
activation, cytokine secretion and an inflammatory response 170. As already 
noted despite similarities in structure, fibromodulin and lumican display 
differential susceptibilities to degradation by MMPs and ADAMTS-4 and -5.  
Thus while fibromodulin is susceptible to degradation, lumican is far less 
susceptible. This may be due to lumicans ability to act as an MMP-inhibitor 
171.  Lumican binds to and completely inactivates MMP-14 activity in B16F1 
melanoma cells 171 inhibiting cell migration, angiogenesis, and cell-
ECM interactions that normally promote tumour progression 172,173.  Lumican 
contains an MMP inhibitory peptide module in LRR-9 named Lumcorin 170. 
MT1-MMP cleaves lumican abrogating this suppressive activity 
in tumour cells 174. 
 
6. SLRPs and cancer  
 Specific roles of lumican in tumour cell regulation 
 The tumour microenvironment decisively controls cancer development 
by establishing a complex interplay between cancer cells and their 
surrounding stromal components which directs disease progression 175. The 
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tumour stroma is composed of collagens, PGs, structural glycoproteins and 
cell adhesive proteins.  Lumican prevents invasion of the ECM by tumour 
cells through intrinsic mechanisms which down-regulate cell signalling 
processes that would otherwise promote cancer cell proliferation 176.  SLRPs 
structurally organize the ECM 177,178and regulate tumour cell proliferation 
through the regulation of angiogenic processes that are required for tumour 
development and cellular migratory processes that are also an intrinsic 
requirement for the establishment of tumour cell masses at remote sites.  
Lumican is associated with clinical outcome in cancer and appears tumour 
specific 179.  Lumican specifically inactivates MMP-14, through which it 
suppresses ECM remodeling, angiogenesis and cellular migration which all 
contribute to an inhibition of tumourogenesis 65,66,170,180-184. 
 
 As seen in Table III, lumican is associated with a diverse range of 
cancer types and plays many functional roles in the affected tissues however 
the role of lumican in cancer varies with tumour type. Lumican is expressed 
and secreted by human melanoma cells but not by normal melanocytes 185.  
Lumican binds to 21 integrin and inhibits melanoma cell adhesion 186. 
Melanoma cell migration is also blocked by inhibiting MMP-14 173, lumcorin a 
peptide derived from lumicans ninth LRR repeat is a potent MMP inhibitory 
peptide. Lumcorin inhibits tumour cell growth 187 and migration 184 through 
alterations in focal adhesion complexes 180.  Actin cytoskeletal organisation 
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has also been shown to be disrupted by lumican binding to 21 integrin in 
A375 melanoma tumour cells 183 and it also inhibits proliferation of B16F1 
melanoma cells and lung metastasis 181.  
 
Lumican also inhibits pancreatic tumour cell growth 188.  Lumican is 
expressed in alpha cells of pancreatic islets and pancreatic cancer cells 189. 
Lumican stimulates growth but inhibits replication and invasion by human 
pancreatic cancer cells 190,191 and in pancreatic ductal adenocarcinoma 192.  
Lumican expression is also up-regulated in lung adenocarcinoma and 
squamous cell carcinoma where it inhibits cell migration and cellular 
proliferation 193,194 but is down-regulated in giant cell bone tumours 195. 
 
Overexpression of lumican upregulates gelsolin and filamentous actin 
reorganization 196 and is associated with a good outcome in Stage II, III colon 
carcinoma 179. However lumican expression in advanced colorectal cancer 
with nodal metastasis correlates with a poor prognosis 197,198. In osteosarcoma 
lumican regulates tumour cell adhesion by modulating TGFβ2 activity 199 and 
is positively correlated with differentiation but negatively with the growth of 
human osteosarcoma cells 200. In prostate cancer an increase 
in lumican expression has been observed in the stromal tissue 
surrounding prostate primary tumours. In-vitro experiments showed 
that lumican inhibited the migration and invasion of 
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metastatic prostate cancer cells isolated from lymph node, bone and brain. A 
significant increase in prostate cancer cell invasion has been observed in the 
peritoneum of lumican knockout mice, demonstrating the inhibitory 
role lumican normally plays in the ECM preventing prostate cancer invasion 
201.  
 
Lumican significantly attenuates breast tumour cell functional properties, 
including proliferation, migration and invasion in-vitro.  Lumican also down-
regulates estrogen receptor / expression in breast cancer cells suppressing 
the expression of major matrix effector molecules such as MMPs and EGFR 
which normally promote breast cancer progression 202.  Low lumican levels is 
associated with a worse prognosis in lymph node-negative 
invasive breast carcinomas 203. 
 
Endometrial cancer is the most frequent type of malignant gynecological 
tumour in the Western world with ~40,000 cases reported annually 204. 
Lumican staining is more intense in endometroid-type endometrial cancer 
than in endometrial intraepithelial neoplasia   although the functional roles of 
lumican in these tissues remains to be fully determined 205.  
 
Lumican is  a cytoplasmic and pericellular component of neuroendocrine 
tumours including carcinoid tumours and neuroendocrine cell carcinomas 
 26 
and their associated stromal tissues.  Lumican is observed in the rough 
endoplasmic reticulum and neuroendocrine granules in neuroendocrine 
tumours as well as the interspaces between collagen fibers in stromal tissues 
and occurs in carcinoid tumours with a higher frequency than in 
neuroendocrine cell carcinomas 206.  High expression levels of lumican in these 
tissues is believed to explain the slow growth rates of such tumours.  
Schwannoma-like salivary pleomorphic adenomas are rare but are associated 
with chondroid tissue formation with the  ectopic chondrogenesis driven by 
BMP-2. Pleomorphic adenomas are the most common form of salivary gland 
tumours.  Lumican is predominantly found in the hyaline (100%) and fibrous 
regions (89.4%) and in chondroid masses in salivary pleomorphic adenomas 
207. 
 
Lumican is expressed in uterine cervical squamous cell carcinoma particularly 
at the periphery of cancer cell nests and by fibroblasts in proximity to these 
tumour cell masses but is not expressed by normal squamous or 
ductal cells close to these cancer cells 208.  The role of lumican in these tumours 
has not been determined however elevated lumican levels at 
the periphery of such cancer cell nests may play regulate the growth or 
invasion of human cervical cancer cells 208. 
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7. Concluding remarks 
KS is an underappreciated GAG of considerable complexity.  This chapter has 
attempted to outline the molecular recognition and information transfer 
properties this biomolecule conveys to a diverse array of interactive KS-PGs 
and the multifunctional roles they have in cellular regulation.  Not only is KS 
attached to an extensive array of PGs with diverse functional properties but it 
also decorates a number of mucin-like glycoproteins of importance in the 
tumour environment.  The interactions KS regulates are of importance in a 
diverse range of physiological processes in health and disease.  A greater 
understanding of the KS glyco-code and how it is interpreted by different cell 
populations will undoubtably pave the way to the elucidation of further 
complexities of this fascinating molecule and its participation in cellular 
regulation in health and disease and may be of application in repair biology.  
 
8.  Future Studies on KS 
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Table I.  Antibodies Developed to KS Illustrate its Structural Complexity 
Antibody Epitope identified Ref 
 
TRA-1-60 
Epitope sensitive to neuraminidase, keratanase-I/II, and 
endo--D-galactosidase.  
Epitope identified Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAc  and 
Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ1-6(Galβ1-
3GlcNAcβ1-3)Galβ1-4Glc this oligosaccharide, is expressed 
on podocalyxcin on pluripotent embryonic stem cells 
 
 
60,209-212 
 
 
TRA-1-81 
Epitope resistant to neuraminidase but sensitive to endo--
D-galactosidase, keratanase-I/II.  Epitope is terminal Galβ1-
3GlcNAcβ1-3Galβ1-4GlcNAc and Galβ1-3GlcNAcβ1-
3Galβ1-4GlcNAcβ1-6(Galβ1-3GlcNAcβ1-3)Galβ1-4Glc 
these oligosaccharides are expressed on cell surface 
podocalyxcin on pluripotent embryonic stem cells 
 
 
60,209-212 
R-10G Low sulphation poly N-acetyllactosamine KS epitope 61,133,134,
213 
 
SSEA-1¶ 
Cell surface glycan of murine embryonic pluripotent stem 
cells, epitope expressed on proteoglycan and glycoprotein 
core proteins and bioactive lipids 
195 
 
“i” antigen¶ 
 
Human autoantibody to a non-branched epitope in non-
sulphated poly-N-acetyllactosamine 
 
214-218 
“I” 
antigen¶ 
Human autoantibody to a branched epitope in non-sulphated 
poly-N-acetyllactosamine regions of KS  
214-218 
4C4 Highly sulphated KS on embryonic tumour cell 
podocalyxcin  
67 
5D4 Hexa-sulphated KS saccharide  122,123 
MZ15 Hepta and octa-saccharide KS oligosaccharides 43,123 
1B4 Tetrasulphated hexasaccharide in linear KS 123 
3D12/H7 Trisulphated fucosylated poly-N-acetyllactosamine KS 
chains located  in the CS 1 and 2 region of aggrecan core 
protein  
219 
D9B1 A sialo-KS epitope on endometrial KS-PGs 102,220,22
1 
6D2/B5 Fucosyl-KS epitope  222 
SV2 High sulphation KS chains on SV2 PG 223,224 
EFG-11 Tri KS disaccharides 225 
1/14/16H9 Specific equine KS antibody  226,227 
 
BKS-1(+) 
D-GlcNAc 6-sulphate KS stub neo-epitope exposed by 
keratanase-I/II, endo -D-galactosidase digestion 
228 
Abbreviations: TRA, Trafalgar antigen/tumour rejection antigen; SSEA. Stage 
specific embryonic antigen. ¶ These antibodies identify non-sulphated epitopes in 
poly-lactosamine regions occurring in KS 
 
 
 
 
 29 
 
 
       Table II  O-glycan core Mucin type acceptor structures sulphated on 
Gal or GlcNAc 
O-glycan acceptor  Mucin source Sulphation position Ref 
core 1  
Galβ1-3GalNAc- 
Rat gastric and 
salivary mucins 
C6 on extending 
GlcNAc 
229 
core 2  
GlcNAcβ1-6Galβ1-3    
Rat mammary 
adenocarcinoma  
C6 on GlcNAc 230-232 
acceptor structure 
unspecified 
Pig gastric 
mucin 
C6 on GlcNAc 233 
core 3  
GlcNAcβ1-3GalNAc-  
repeat NAcetyl 
lactosamine 
disaccharides 
 
pig zona 
pellucida 
glycoproteins 
 
C6 on GlcNAc in  
O- and N- linked 
glycans 
 
97 
Specific acceptor 
structure not specified 
Cystic fibrosis 
respiratory 
mucins  
C3 on Gal and C6 on 
GlcNAc on multiple 
complex O-glycans 
234-236 
core 6  
GlcNAc β1-6GalNAc- 
Rat bone 
sialoprotein 
C6 on GlcNAc 99 
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  Table III Lumican influences many different tumour types 
Tumour type Features affected by lumican Ref 
melanoma  
A375, B16F1 cells 
Inhibition of MMP-14 and tumour cell 
attachment and proliferation. 
170,173,180,184,185,187,237 
 
 
pancreatic cancer 
Inhibition of tumour cell growth 188.  
Lumican is expressed in alpha cells of 
pancreatic islets and pancreatic cancer 
cells 189. Lumican stimulates growth 
and inhibits replication and invasion of 
human pancreatic cancer cells 190,191 and 
pancreatic ductal adenocarcinoma 192. 
 
 
188-192 
 
giant cell bone 
tumour 
Down-regulation of lumican may serve 
as a biomarker of metastatic and 
recurrent giant cell bone tumours 
 
201 
 
prostate cancer 
Anti-tumour activity. Inhibition of the 
migration and invasion of lymph node, 
bone and brain metastatic prostate 
cancer cells  
 
238 
 
colon carcinoma 
 
 
 
colorectal cancer 
Overexpression of lumican upregulates 
gelsolin and filamentous actin 
reorganization 196 and is associated 
with good outcome in Stage II, III 
Colon carcinoma 179.  
Lumican expression in advanced 
colorectal cancer with nodal metastasis 
correlates with poor prognosis. 
 
 
179,196 
 
 
197,198 
 
 
osteocarcinoma 
Regulates tumour cell adhesion by 
modulating TGFβ2 activity 199.  
Lumican expression is positively 
correlated with the differentiation and 
negatively with the growth of human 
osteosarcoma 200. 
 
 
64,65 
   
breast cancer                                    
Reduced expression of lumican is 
associated with poor outcome in node-
negative invasive breast cancer.  
Lumican influences ECM organisation. 
 
239,240 
 
 
adenocarcinoma  
and squamous cell 
carcinoma of lung 
Upregulation of lumican inhibits 
tumour cell migration, and cellular 
proliferation  
 
194 193,194 
 
carcinoid 
tumours,  
Cytoplasmic lumican in 
neuroendocrine tumour cells is 
associated with the RER, cellular 
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neuroendocrine 
cell carcinoma 
granules and the interspaces of stromal 
collagen fibers.  Higher cytoplasmic 
expression of lumican in carcinoid 
tumours compared to neuroendocrine 
carcinomas may slow the growth of the 
former tumour cells. 
 
206 
salivary 
pleomorphic 
adenomas 
Lumican expression is associated with 
the formation of mesenchyme-like 
elements in salivary pleomorphic 
adenomas.  
 
207 
uterine cervical 
cancer 
lumican protein accumulates in uterine 
cervical cancer cells at the periphery of 
cancer nests 
208 
 
endometrial 
cancer 
Endometrial cancer is the most 
common form of malignant 
gynecological tumour.  Lumican is 
strongly associated with these tumours 
however it’s functions in such tumours 
still has to be determined 
 
 
204,205 
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Figure legends 
Figure 1.  The structural heterogeneity of KS assembled from the repeat 
disaccharide D-Gal-GlcNAc-6-sulphate showing pertinent features of Corneal 
KS-I and its di-, mono-, non sulphated and linkage regions plus fucose and 
sialic acid end-capping structures (a) and of equivalent regions in skeletal KS-
II isolated from weight bearing connective tissue (b) and KS-II from non-
weight bearing connective tissue (c) and brain KS-III (d). 
Figure 2. 
This figure is reproduced from the KEGG KS biosynthesis reference data  map 
(Map 00533) [http://www.kegg.jp/kegg-bin/show_pathway?map00533] which 
shows the major known KS biosynthetic enzymes. 
Figure 3.   
Putative antibody recognition sites on native undigested KS-I (a) and 
keratanase-I, keratanase-II and endo--D-galactosidase cleavage sites on the 
KS chain (b) which generate the neo-epitope BKS-1 (+) stub KS epitope.  
Figure 4 
Immunolocalization of the 5D4 positive KS epitope synthesised by microglial 
cells and macrophages in rat spinal cord follow spinal cord injury.  The 
arrows indicate glial cells (G) and macrophages (M) which synthesise 5-D-4 
KS.  Areas of co-localization are indicated in yellow. Modified from 73 with 
permission under the auspices of Creative Commons Attribution 4.0 
International License (CC-BY). 
Figure 5. 
KS localised in mucus and mucins of the mucosal surface of human 
tracheobronchial epithelial cell cultures visualised using Haematoxylin and 
Eosin (a), Alcian blue-periodic acid Schiff staining (b) or by 
immunolocalisation of MUC5AC, MUC5B (c) and KS (MAb 5D4)(d) using 
specific antibodies.  Panels c and d were counterstained with DAPI to 
visualise cell nuclei.  Note the height of the accumulated mucus layer ~100 
m, the intense staining of KS in the periciliary layer and plumes of material 
extending from the ciliary tips into the mucus ciliary plumes (d) while 
excluding the polymeric mucins in panel (c).  Intracellular mucins are not 
apparent in these images since their fluorescence intensities did not reach the 
detection threshold appropriate for use in the visualisation of the strong 
extracellular immunolocalisations .  Scale bar 20 m.  Figure reproduced from 
94 with permission, , Springer Nature, Mucosal Immunology (license number 
4605370414328). 
Figure 6.   
Structural representations of the major extracellular and cellular CNS/PNS 
KS-Proteoglycans.   Aggrecan (a), podocalyxcin (b), RPTP- (c), phosphacan 
(d) and SV2 proteoglycan (e).  Note that the structure depicted in (a) is of 
human aggrecan, rat aggrecan does not have a KS-rich region. Figure 
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modified from 15 with permission under the auspices of Creative Commons 
Attribution Non-Commercial License http://creativecommons.org/licenses/by-
nc/4.0/. 
Figure 7.   
Domain structure of KS substituted SLRP family members which are found in 
the CNS/PNS, and tensional and weight bearing connective tissues figure 
adapted from167 with permission Elsevier, Biochim Biophys Acta (license 
number 4605380480747). 
Figure 8.   
Upregulation of podocalyxcin expression in astrocytoma in the brain.  
Normal brain tissue showing an absence of detectable podocalyxcin (a).  
Assorted views of astrocytomas and immunolocalisation of podocalyxcin (b-
f).  Images a-c  modified from 47 with permission Elsevier, Biochemical and 
Biophysical Research Communications (license number 4605390803553). 
Images d-f modified from 62 with permission Elsevier, Biochemical and 
Biophysical Research Communications (license number 4605390045819).  
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